FYN, A CRAZY GENE...

IT DOES NOT KNOW WHEN TO STOP INTERACTING
IT IS INVOLVED IN CRAZINESS (ALZHEIMER'S)
BUT YET IT KEEPS DOING ITS THING.
CAN WE STOP IT ELECTIVELY?
WE ARE WORKING HARD!

FYN

From Wikipedia, the free encyclopedia

Jump to: navigation, search

FYN oncogene related to SRC, FGR, YES
PDB rendering based on 1a0n.
Available structures PDB Ortholog search: PDBe, RCSB [show]List of PDB id codes
Identifiers
Symbols	FYN; SLK; SYN; p59-FYN
External IDs	OMIM: 137025 MGI: 95602 HomoloGene: 48068 ChEMBL: 1841 GeneCards: FYN Gene
EC number	2.7.10.2
[show]Gene Ontology
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	2534	14360
Ensembl	ENSG00000010810	ENSMUSG00000019843
UniProt	P06241	P39688
RefSeq (mRNA)	NM_001242779	NM_001122892
RefSeq (protein)	NP_002028	NP_001116364
Location (UCSC)	Chr 6: 111.98 – 112.19 Mb	Chr 10: 39.37 – 39.57 Mb
PubMed search	[1]	[2]
This box: view talk edit

Proto-oncogene tyrosine-protein kinase Fyn is an enzyme that in humans is encoded by the FYN gene.^[1]
This gene is a member of the protein-tyrosine kinase oncogene family. It encodes a membrane-associated tyrosine kinase that has been implicated in the control of cell growth. The protein associates with the p85 subunit of phosphatidylinositol 3-kinase and interacts with the fyn-binding protein.

Interactions

FYN has been shown to interact with:

• ADD2^[6]
• Alpha-tubulin 3C,^[7]
• BCAR1^[8][9]
• Cbl gene^[10][11]
• CBLC^[12]
• CD36^[13][14]
• CD44^[15]
• CDH1^[16]
• CHRNA7^[17]
• Colony stimulating factor 1 receptor^[18]
• C-Raf^[19]
• CTNND1^[16][20]
• DLG4^[21][22]
• Dystroglycan^[23]
• EPHA8^[24]
• Fas ligand^[25][26]
• FYB^[27][28]
• GNB2L1^[29][30]
• GRIN2A^{[21][22][31][32]}
• ITK^[33][34]
• Janus kinase 2,^[35]
• KHDRBS1^[36][37]
• Nephrin^[38][39]
• PAG1^[40]
• PIK3R2^[41]
• PRKCQ^[42]
• Protein unc-119 homolog^[43]
• PTK2^[44][45]
• PTK2B^[46][47][48]
• RICS^[49]
• SH2D1A^[50][51]
• SKAP1^[28][52][53]
• Syk^[11]
• Tau protein^{[7](ALZHEIMER LOCATED HERE PEOPLE!)}
• TNK2,^[54]
• TrkB^[55]
• TRPC6^[56]
• Tyrosine kinase 2^[57]
• Wiskott-Aldrich syndrome protein^[58][59][60]
• ZAP-70^[61]

References (WIKIPEDIA)

WITH THIS MANY INTERACTIONS, IT IS A CRITICAL GENE, BUT WATCH OUT NOW, IT NEEDS TO BE HANDLED WITH CARE.  HIT IT ONLY IN A VERY SELECTIVE FASHION NOW! OR YOU LOSE THE HOST!

 

another crazy gene

 

Androgen receptor has been shown to interact with:

• AKT1,^[38]
• BAG1,^[39][40][41]
• Beta-catenin,^{[42][43][44][45][46][47]}
• BRCA1,^[48][49]
• C-jun,^[50]
• Calmodulin 1,^[51]
• Caveolin 1,^[52]
• CDK9,^[53]
• COX5B,^[54]
• CREB-binding protein,^{[55][56][57][58]}
• Cyclin D1,^[59][60]
• Cyclin-dependent kinase 7,^[61]
• Death associated protein 6,^[62]
• Deleted in Colorectal Cancer,^[63]
• EFCAB6,^[64]
• Epidermal growth factor receptor,^[65][66]
• FOXO1,^[67]
• GAPDH,^[68]
• Gelsolin,^[69]
• GNB2L1,^[70]
• GSK3B,^[71]
• HDAC1,^[72]
• HSP90AA1,^[73][74]
• HTATIP,^[72]
• MAGEA11,^[75][76]
• MED1,^[77]
• MYST2,^[78]
• NCOA1,^[43][79][80]
• NCOA2,^{[42][57][75][81][82]}
• NCOA3,^[81][83][84]
• NCOA4,^{[38][82][85][86][87][88][89][90][91]}
• NCOA6,^[92]
• NCOR2,^[42][93][94]
• NONO,^[57]
• PA2G4,^[95]
• PAK6,^[96][97]
• PATZ1,^[98]
• PIAS2,^[99][100]
• PRPF6,^[101]
• PTEN,^[102]
• RAD9A,^[103]
• RANBP9,^[104]
• RCHY1,^[105]
• Retinoblastoma protein,^[106][107]
• RNF14,^{[82][85][108][109]}
• RNF4,^{[98][110][111]}
• SART3,^[112]
• SMAD3,^{[113][114][115]}
• Small heterodimer partner,^[116]
• Src,^{[102][117][118]}
• SRY,^[119]
• STAT3,^[120][121]
• SVIL,^[122]
• Testicular receptor 2,^[123]
• Testicular receptor 4,^[124]
• TGFB1I1,^[85][125]
• TMF1,^[126]
• TRIM68,^[127]
• UBE2I,^{[42][43][128][129][130][131]}
• UXT,^[132] and
• ZMIZ1.^[133]

 wikipedia! remember what we said about short stature

this one also is that kind, lack of it lead to short stature so it it is a powerful gene, suppression here cures prostate cancers!

Medscape Medical News from the:

NCCN Issues New Treatment Guidelines for Penile Cancer

Roxanne Nelson

Mar 22, 2013

Drug & Reference Information

• Penile Cancer
• Urogenital Squamous Cell Carcinoma
• Pelvic Lymph Node Dissection

Hollywood, Florida — The National Comprehensive Cancer Network (NCCN) has issued new treatment guidelines for penile cancer.
"The first thing people ask me is why develop guidelines for such a rare cancer," said Philippe  E. Spiess, MD, genitourinary oncologist at the H. Lee Moffitt Cancer Center in Tampa, Florida.
In 2010, an estimated 1250 new cases of penile cancer were diagnosed in the United States and there were about 310 related deaths. Penile cancer accounts for 0.4% to 0.6% of all malignant neoplasms in the United States and Europe.

Dr. Philippe Spiess

Dr. Spiess presented highlights of the guidelines here at the NCCN 18th Annual Conference.
There is a high degree of heterogeneity in the way penile cancer is treated in North America and globally, he explained. "The standard of care remains complete tumor excision and eradication of negative margins."
However, there has been increasing consideration of less or noninvasive management of primary penile tumors, based on stage and grade, he added.
Less and Noninvasive Therapy
For carcinoma in situ and superficial verrucous carcinoma, a British study showed that 5-fluorouracil or imiquimod produced response rates of 60% to 70% at 5 years (World J Urol. 2009;27:179-187). In this setting, CO₂ and Nd:YAG laser ablation can also be used, although retreatment rates are quite high (about 20% to 30%), explained Dr. Spiess.
Total gland resurfacing and wide local excision with circumcision are also options.
There is some evidence for the use of topical therapies. In a recent retrospective review of all primary and recurrent cases of penile carcinoma in situ treated with topical 5-fluorouracil and imiquimod over a 10-year period (Eur Urol. 2012;62:923-928), "the response rates were excellent," said Dr. Spiess. "A complete response was seen in 57% of the patients, with a partial response in 14%."
No response was seen in the remaining 29.5% of patients, but none of the patients recurred or progressed. Toxicity was also low; 10% of patients reported local toxicity and 12% reported an adverse event.
Another study, looking at penile-preserving surgery for patients with penile Tis and PT1 tumors, found that there was a recurrence rate of 21.4% in both subgroups (J Urol. 2011;186:1303-1307). At 5 years, 13.8% of patients had a late recurrence, but none of the patients with pTis tumors had progressed to invasive or metastatic disease.
"These patients can recur fairly late, so it is important to follow them for at least 10 years," Dr. Spiess pointed out.
"As far as penile-preserving therapy, the take-home message is that clinical stage is everything," Dr. Spiess explained. However, he went on to emphasize that "it has to be a patient with a small superficial lesion, where you can obtain negative margins. If you can't, then you need to look at more radical options in surgery."
Another treatment option is brachytherapy. A recent French study found a 10-year penile recurrence rate of 20% and a 10-year inguinal recurrence rate of 11% (Int J Radiat Oncol Biol Phys. 2009;74:1150-1156). However, "centers of excellence that have experience with penile brachytherapy are few and far between," he cautioned. "That's why the guidelines...are somewhat cautious in making recommendations until we see a wider experience using penile brachytherapy."
He emphasized the importance of stringent surveillance after radiotherapy to the penis; up to 40% of patients who receive radical radiotherapy will eventually need surgery for disease recurrence. Surgery in this population can be challenging because irradiated tissues are brittle and poorly vascularized, making them less than ideal for grafting.
Sentinel Node Biopsy

Learn about evolving data on EGFR mutation and ALK rearrangements in NSCLC. It can impact your decision to test for biomarkers.

Review the data

OC468500PROF-E 10/12

Information from Industry

Dr. Spiess discussed the concept of sentinel lymph node biopsy in penile cancer, which was proposed more than 30 years ago. One study reported a false-negative rate of 18% using a combined preoperative injection of technetium-99m labeled sulfur colloid and isosulfan blue dye (J Urol. 2002;168:76-80).
A more recent prospective study found a sensitivity of only 71%, with 2 false-negative results reported (J Urol. 2007;177:2157-2161). But a review found that false-positive results can be minimized with preoperative ultrasound and fine-needle aspiration cytology on suspicious nodes (World J Urol. 2009;27:197-203).
However, this technique has not yet been embraced in this setting. "We are somewhat cautious about promoting this technique, although clearly it is something very interesting and something that can be used at a center that has high expertise in sentinel lymph node biopsy," said Dr. Spiess. "At this point, it is not being widely used in North American centers."
National Comprehensive Cancer Network (NCCN) 18th Annual Conference.

 

ON THE CPRIT FRONT THE DANCE GOES ON!

You're viewing a lite version of ynn.com
Time Warner Cable customers: Sign in with your TWC ID for video access.
Get my TWC ID. | Get TWC service. | Read the FAQ.

• Print
•  0 0 0 3

04/09/2013 08:11 PM

CPRIT executives grilled by lawmakers

By: John A. Salazar

Executives for the Cancer Prevention and Research Institute of Texas were being grilled by state lawmakers Tuesday. The organization is currently under criminal investigation and an audit showed millions of dollars in scientific grant funds went out, but results weren't coming in.
For House committee members, Tuesday’s meeting was all about trust, transparency, and accountability.
"How can we expect public trust to be reaffirmed?" Republican committee member Dan Flynn said.
Four months after a criminal investigation began on the Cancer Prevention and Research Institute of Texas, Transparency Committee members continue to look for answers.
Questions surrounded the non-scientific grant approval for Dallas-based Pelaton Therapeutics, worth $11 million dollar.
Suspicions of grant-rigging went public in November of last year.
"When it appeared that the grant report was missing information or inaccurate, I immediately called for an investigation,” Jimmy Mansour, CPRIT chairman, said.
The CPRIT chief told the committee that $3 million dollars of that public money grant will not be recovered.
"And that is regrettable that much is lost," Mansour said.
To date three people have left CPRIT while under criminal investigation. Committee members want to know if only those three misled the entire agency.
Committee members also wanted to know how public trust could be restored in the CPRIT executives, the same executives who brought scrutiny to the cancer agency.
They also criticized the renaming of the fundraising entity of CPRIT, the CPRIT Foundation. That name change came about two weeks ago. Committee members said any money raised by the foundation needs to be returned to the state.

• 
  
• 
  

==============================================
How can this organization survive such a lengthy, protracted war and come out winning?
One thing for sure it will never be the same and will come out weaker and slim!  another win for cancer and another impediment to the CURE.   The cure is with us, we just complicate our minds with politics and favoritism.  What a waste!  I still pray for CPRIT...SAVIOR PLEASE COME UPON THIS ORGANIZATION!...

ACTIVITIES AT CRBCM

*COMPLETED INDIANA WORK
BACK IN EL PASO, TX
Initiated therapy for Angiosarcoma with trial of Avastin alone at this point thanks to drug company help.
will try 3-4 infusions and reassess.  Votrient still an option.  But remember (OUR PT developed severe skin reaction to taxanes and had received MAID)
-------------------------------------------------------------------------------

J Am Acad Dermatol. 2010 Oct;63(4):e83-4. doi: 10.1016/j.jaad.2009.09.035.

Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy.

Fuller CK, Charlson JA, Dankle SK, Russell TJ.

--------------------------------------------------------------------------------------------

 

Avastin alone has proven to be effective.

 

 Case Report"Scalp Angiosarcoma Remission with Bevacizumab and Radiotherapy without Surgery: A Case Report and Review of the Literature, " DE YAO et al.

=========================================================================

*Also we are searching for a surgeon who would consider resecting a Pancreatic cancer with mesenteric VEIN NOT ARTERY involvement.  we are shrinking the tumor with chemotherapy and Radiation, will reassess result radiologically.  Call me if you can help!

=============================================

DON'T LOOK FOR ME THIS WEEK-END

WILL BE HARD AT WORK!

Prostate Symposium

Dear Dr.Mutombo Kankonde,

Below is the link for the agenda for the Prostate Symposium research event on April 13, 2013 in Las Vegas.  Below you will find the agenda link and hotel information:  

Agenda_ProgramBook_CCProstate_LasVegas_4-1-13.pdf

Meeting Information:

Mandarin Oriental

3752 Las Vegas Blvd South

Las Vegas, Nevada 89158

(702) 590 8888

Meeting: Ballroom B, 3^rd Floor

WILL LOSE SOME MONEY BUT THAT COMES WITH THE TERRITORY!  BELIEVE ME IT'S HARD TO MISS THE ACTION, WILL TRY TO BE GOOD COLLECTED AND UNDER CONTROL.

THANKING THE ORGANIZER FOR INVITING ME, WILL LEARN PLENTY OF GOOD STUFF FOR THE BLOG AND FURTHER RESEARCH!

==================================================

WILL PUBLISH OUR BLOG STATISTICS AS SOON AS WE HIT 15000 REVIEWS WHICH WE PROJECT WILL BE IN 2-3 DAYS AT CURRENT PACE OF ATTENDANCE!  CRBCM, WE ARE HARD AT WORK!

T-DM1 IS NOT ALONE AND TARGET THERAPY WILL LEAD US TO NEW MEDICATION EVERYDAY : GET THIS!

"DMUC5754A consists of a monoclonal antibody against the protein MUC16, found on ovarian cancer cells at high levels, and a toxin linked by a cleavable linker. Approximately 80% of ovarian cancer patients have tumors that have high expression of MUC16 (also known as CA-125), according to Liu. The toxin is the microtubule-disrupting agent monomethyl auristatin E (MMAE). The antibody directs the toxin specifically to ovarian cancer cells to kill them. Because the antibody delivers the toxin specifically to the ovarian tumor, an especially potent toxin can be used, one that would be too toxic as a general cytotoxic agent that would also affect healthy tissue." NEWS FROM GENENTEC SOURCE

 

Home » CONFERENCES » AACR 2013

CONFERENCE REPORT  AACR: Antibody-Drug Conjugate Shows Promise in Platinum-Resistant Ovarian Cancer By Anna Azvolinsky, PhD1 | April 9, 2013 1Freelance Science Writer and Cancer Network Contributor. Follow Her on Twitter Washington, DC—A novel therapy has shown activity in treatment of difficult-to-treat, advanced, platinum-resistant ovarian cancer. The drug, DMUC5754A (Genentech), is part of a new class of drugs called antibody-drug conjugates. The phase I trial results were presented at the American Association for Cancer Research (AACR) Annual Meeting, held April 6–10 in Washington, DC by Joyce F. Liu, MD, MPH, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston. Ovarian cancer as seen on CT; source: James Heilman, MD, Wikimedia Commons “Overall the drug was well tolerated, with a toxicity profile that is comparable to other therapeutics currently used in clinical practice,” Liu told Cancer Network. “We think the results are very encouraging in a patient population where response to other therapies is limited.” (MORE: AACR: Anti-PI3K/MEK Inhibitor Targeted Therapy Combo Shows Activity) DMUC5754A consists of a monoclonal antibody against the protein MUC16, found on ovarian cancer cells at high levels, and a toxin linked by a cleavable linker. Approximately 80% of ovarian cancer patients have tumors that have high expression of MUC16 (also known as CA-125), according to Liu. The toxin is the microtubule-disrupting agent monomethyl auristatin E (MMAE). The antibody directs the toxin specifically to ovarian cancer cells to kill them. Because the antibody delivers the toxin specifically to the ovarian tumor, an especially potent toxin can be used, one that would be too toxic as a general cytotoxic agent that would also affect healthy tissue. The results from the phase I trial also showed that those patients who had the highest expression of MUC16, the target of the antibody portion of the drug, derived the most benefit from the treatment. This is likely to facilitate the selection of only those patients who are most likely to benefit from treatment in future trials. Platinum-resistant, advanced ovarian cancer has an unmet need and is difficult to treat. Patients currently have few treatment options. Platinum-based chemotherapy remains the standard way to treat ovarian cancer, and platinum resistance is a major treatment challenge. The phase I trial evaluated various doses of DMUC5754A in advanced ovarian and pancreatic cancer patients. DMUC5754A was administered at doses ranging from 0.3 mg/kg to 3.2 mg/kg every 3 weeks. Forty-four patients with advanced, recurrent, platinum-resistant ovarian cancer enrolled; of those, one complete response and four partial responses were reported. All patients who responded were treated with a 2.4 mg/kg dose of the drug and had high MUC16 expression in their tumor cells. Six additional patients had minor responses. Fatigue was the most common adverse event at all dose levels, occurring in more than half of all patients. Other common adverse events were vomiting, decreased appetite, nausea, diarrhea, and peripheral neuropathy. Peripheral neuropathy was manageable and reversible in most patients through dose delay and dose reductions, according to the researchers. Grade 3 adverse events included fatigue and neutropenia, both occurring in 9% of patients. Neutropenia and uric acid release were the only dose-limiting toxicities during the study. Both occurred at the maximum 3.2 mg/kg dose. Other serious drug-related adverse events were small intestine obstruction in two patients, hypocalcemia in a single patient, and neutropenia in a single patient. “Neuropathy, which was an anticipated potential toxicity of the drug, did occur, but was manageable and typically reversible with dose reductions or delays,” said Liu. The role of MUC16 in cancer development and progression is not yet clear. The protein is a large transmembrane protein that is found in abundance on ovarian cancer cells but not healthy tissue. Researchers speculate that the protein may help ovarian tumor cells bind to mesothelial cells that line the peritoneal cavity. The encouraging activity and safety profile of the antibody-drug conjugate warrants further trials in ovarian cancer patients, according to the study researchers. “I think the major remaining question is how this therapy compares against the standard treatments that we use in platinum-resistant ovarian cancer,” said Liu. Discussions for further development of DMUC5754A, including a phase II ovarian cancer trial, are ongoing.

In a retrospective review of Lung cancers , use of Beta blockers may provide survival advantage

*In a retrospective review of Lung cancers , use of Beta blockers may provide survival advantage.

*Ruloxitinib, still the success story in JAK driven diseases.  For JAK driven disease to be seen more in Hematologic malignancy, the receptors for hematologic growth hormones must be stimulated.
COMFORT-1 showed 41.9% of patients on Ruxolitinib had spleen reduction  but in COMFORT-2, only 28% had spleen reduction by week 48.

The JAK inhibitors are now being tried in Pancreatic cancers!

*Obstruction to Cure is not only found in limitation of progress in science, but in man made complications such disparities in funding availability and managed care obstruction to access to known medications!  Cure escapes us for our own doing, in a summary!

*In Breast Cancer, Inhibitors to CD4,6 are proving to be a new approach when given with Letrozole

*In Prostate cancer don't be too eager to use Steroids with enzalutmide.  Steroids may "activate androgen receptors promoting the cancer".   I should confess this point is a bit controversial since that's what we do, stimulate to better kill with chemotherapy (Taxotere-Cabazitaxel).  But the logic may not work for another hormone used for killing.

*In Tivo-1,
they found no survival advantage for TIVOZANIB Vs Sorafenib in patient with Renal Cancer.
Tivozanib is said to be more potent and selective for VEGF receptors!  PFS was superior though with TIVO!

*Check this out!  The global multikinase inhibitor Regorafenib (blocks VEGFR1,KIT,TIE2,PDGFR and RET) got approved for GIST.  patients received 160 mg PO daily x21 Q28. Watch for fatigue hand foot sundrome diarrhea, loss of appetite,HTN,weight loss,rash and fever.  and being an anti-VEGF, bleeding and intestinal perforation of course!  rare cases of Coronary attacks!
*New kid on the block, RAMUCIRUMAB TRIED IN GASTRIC CANCER!

(READ TARGETED THERAPY NEWS)

New Software Identifies and Stratifies Risk Posed by Lung Nodules

Apr. 8, 2013 — A multidisciplinary team of researchers at Mayo Clinic has developed a new software tool to noninvasively characterize pulmonary adenocarcinoma, a common type of cancerous nodule in the lungs. Results from a pilot study of the computer-aided nodule assessment and risk yield (CANARY) are published in the Journal of Thoracic Oncology.

"Pulmonary adenocarcinoma is the most common type of lung cancer and early detection using traditional computed tomography (CT) scans can lead to a better prognosis," says Tobias Peikert, M.D., a Mayo Clinic pulmonologist and senior author of the study. "However, a subgroup of the detected adenocarcinomas identified by CT may grow very slowly and may be treatable with less extensive surgery."

CANARY can noninvasively stratify the risk lung adenocarcinomas pose by characterizing the nodule as aggressive or indolent with high-sensitivity, specificity and predictive values.

CANARY uses data obtained from existing high-resolution diagnostic or screening CT images of pulmonary adenocarcinomas to match each pixel of the lung nodule to one of nine unique radiological exemplars. In testing, the CANARY classification of these lesions had an excellent correlation with the microscopic analysis of the surgically removed lesions that were examined by lung pathologists, Dr. Peikert says.

Lung cancer is the leading cause of cancer-related deaths in the United States.

"Without effective screening, most lung cancer patients present with advanced stage disease, which has been associated with poor outcomes," Dr. Peikert says. "While CT lung cancer screening has been shown to improve patient survival, the initiation of a nationwide screening program would carry the risk of overtreatment of slow growing tumors and would be associated with substantial health care costs. CANARY represents a new tool to potentially address these issues."

 http://www.sciencedaily.com/releases/2013/04/130408133044.htm

View all JNCCN CE Opportunities

NCCN Flash Updates™: NCCN Guidelines Updated NCCN Flash Update sent March 25, 2013 NCCN has published updates for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL). These NCCN Guidelines® are currently available as Version 1.2013. Ph-negative ALL (ALL-5 and ALL-6) For consolidation options in AYA patients and Adults (age > 65 years), factors to consider for allogeneic HSCT modified to include poor-risk cytogenetics and to remove WBC counts (except as a footnote for the latter). Relapsed/Refractory ALL (ALL-7) The treatment recommendations for AYA and Adult patients consolidated. The following footnote added for allogeneic HSCT: For patients relapsing after allogeneic HSCT, a second allogeneic HSCT and/or donor lymphocyte infusion (DLI) can be considered. Donor lymphocyte infusion (DLI) removed as a treatment option for Ph+ ALL (except as a footnote, as mentioned above). Supportive Care (ALL-B) Prophylactic anti-infectives (ALL-B 1 of 4) The following added: VZV prophylaxis (eg, acyclovir) for at least 1 year after HSCT in transplant patients; and HBV prophylaxis (eg, adefovir, entecavir, lamivudine) for at least 6-12 months after HSCT depending on HBV serology. Steroid management (ALL-B 1 of 4) The following added: Consider dose reduction for steroid-induced psychosis and mood alteration. Asparaginase Toxicity Management (ALL-B 3 of 4) Toxicity grade clarified as CTCAE. Toxicity grades changed from 2, 3, 4 to 1, 2, 3-4. Systemic allergic reaction/anaphylaxis: recommendations for dosing substitutions removed. Pancreatitis; Grade 1 and 2 recommendations combined: Continue asparaginase for asymptomatic amylase or lipase elevation >3.0 x ULN (chemical pancreatitis) or only radiologic abnormalities; observe closely for rising amylase or lipase levels. Continue pegaspargase for nonsymptomatic chemical pancreatitis but observe patient closely for development of symptomatic pancreatitis for early treatment. Grade 3 and 4 recommendations combined: Permanently discontinue all asparaginase for clinical pancreatitis (vomiting, severe abdominal pain) with amylase or lipase elevation >3 x ULN for >3 days and/or development of pancreatic pseudocyst. Asparaginase Toxicity Management (ALL-B 4 of 4) Non-CNS hemorrhage; Grade 2 to 4 recommendations combined: For bleeding in conjunction with hypofibrinogenemia, withhold asparaginase until bleeding £ grade 1, until acute toxicity and clinical signs resolve, and coagulant replacement therapy stable or completed. CNS hemorrhage; Grade 1 and 2 recommendations combined: Discontinue all asparaginase; if CNS symptoms and signs are fully resolved and significant asparaginase remains to be administered, may resume asparaginase therapy at a lower dose and/or longer intervals between doses. CNS thrombosis; Grade 2 recommendation modified with the addition of “with closely monitored anticoagulation.” Evaluation and Treatment of Extramedullary Involvement (ALL-C) CNS leukemia clarified as having CNS-3 and/or cranial nerve involvement. Principles of Chemotherapy (ALL-D) Induction regimens for Ph-positive ALL (ALL-D 1 of 4) Adult patients aged ³40 years; the following treatment option added: TKIs + vincristine + dexamethasone. Protocols for AYA patients aged 15-39 years; the following treatment options added: TKIs + hyper-CVAD: imatinib or dasatinib; and hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate, and cytarabine. TKIs + multiagent chemotherapy: imatinib; and daunorubicin, vincristine, prednisone, and cyclophosphamide. Maintenance regimens (ALL-D 1 of 4) Modified to: Monthly vincristine/prednisone pulses (for 2-3 years). May include weekly methotrexate + daily mercaptopurine (6-MP) as tolerated. The following footnote added: May be necessary to reduce dose/eliminate antimetabolite in the setting of myelosuppression and/or hepatotoxicity. Salvage regimens for relapsed/refractory ALL (ALL-D 3 of 4) Ph-positive ALL; Ponatinib added as a treatment option. Treatment Options Based on BCR-ABL Kinase Domain Mutation Status (ALL-G) This table was updated to include Ponatinib. The Discussion section was updated to reflect all changes within the algorithm. For the complete updated versions of the NCCN Guidelines, the NCCN Drugs and Biologics Compendium (NCCN Compendium®), and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org. To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers. To view the NCCN Guidelines for Patients®, please visit NCCN.com. Free NCCN Guidelines mobile apps for iPad and Android are now available! Visit NCCN.org/mobile/tablet.

PUTATIVE TARGETS IN HEPATOMA
------------------------------------------
It is evident that Hepatocarcinoma which develops most of the time within a cirrhotic liver, result from stress
putting the NF-kB, c-JUN and c-Fos front and center into the pathogenesis of this disease.  The result is an overexpression of Cyclins and Growth factors (TGF).  In fact researchers have reported as a critical step into Hepatogenesis Mutations in the the receptor of TGF.  Making Interferon alpha a potential Target therapy.  It is often time reported that for the above pathway to perform fully a balance in Polyamines should existence (measured by spermidine and Putresssine in one study).  Making Polyamine levels a target for therapy.  Recently, Interferon Regulator factor 4 (IRF4 or MUM1) had become a center of research in Melanoma.  One may wonder if it has the same importance in Hepatoma.   This IRF4 is regulated MITF which we commented on earlier.
The disease will eventually grow and metastasize using standard VEGF/EGFR pathways and Multikinases  are now standard of care.  The Anti-MEK are waiting in a wing for testing.  c-JUN belong to the MAPK family, therefore the MTOR inhibitor are waiting for further testing (May be in combination to interferon).
The genes of hepatic differentiation, the IGF, NF1, hSRC, Axin1, P53,SMAD2-4, TIMP2,Rb1,Bcl-10 and others all appears legitimate target.  We have our work cut out, let's go to work!

CELL IN CANCER MODE

In a normal cell, things are operating normally.  The cell feeds itself and uses energy to allow its normal functions to unfold, and knowing that hard times will come to it, it even puts some energy aside for reserve. When one looks at Mitochondrial activity, one will find Gluconeogensis in full display.  This Normal Metabolism that some have called NORMAL CELLULAR MODE tends to show anabolism and normal oxygen.  In clear Hypoxic conditions which are read by the cell as a stress, there is the reversal of the chemical reactions as catabolism ensue and Fatty Acid become the source of energy and Glycolysis enters into play.   Under these circumstances, which can occur in normal life, catabolism is accompanied with Glycolysis.

In 1920, Walburg described the Walburg effect which characterizes the CANCER CELL MODE.
Indeed in cancer there is a dissociation of Glycolysis and with Catabolism.  In Cancer mode, the cell adopts Glycolysis and Anabolism.  Glycolysis is to escape the normal requirements of constant feeding, be in a stress like while Making new proteins (Anabolism) to allow cell division and proliferation.  One hundred years after the Walburg effect was described, it is now molecularly explained by Researchers.  Indeed, to do this the cell induces a genetic controlled hypoxia  by suppressing SIRT3 which overexpresses HIF.  This induces Hypoxic conditions in the Mitochondria.

http://onlinedigeditions.com/publication/?i=104782&p=12

The Cancer mode can now be measured
but quantifying:
1 Pyruvate Dehydrogenase kinase
2. Over-expression of GLUT1
3. level of vascular endothelial growth factor
4. level of suppression of SIRT3 and related  Increase in ROS1
5. level of HK2, IDH, and SOD3

and if you are very smart, start by including c-JUN, HIF, Myc and TCA (fatty acid)

And as you progress with the clues given you will understand why overexpression of ROS1 could predict resistance to MTOR Inhibitors.   And I believe it predicts of low participation of MAPK as a driver of pathogenesis therefore decreasing the value of MTOR inhibitors.  more detail to come.

ANOTHER WAY OF INDUCING HIF:
"Description

Dimethyloxaloylglycine (DMOG) is an inhibitor of PHF (prolyl hydroxylase, PHD) and asparaginyl hydroxylase FIH-1 (Factor inhibiting HIF, FIH). DMOG has been observed to upregulate HIF (hypoxia stabilize) HIF-1α at specific concentrations. In HMEC-1 cells DMOG attenuated REF-1 (redox factor 1) through activation of HIF. PHT cells exposed to DMOG were observed to upregulate the FSTL3 (follistatin-like 3) transcript. Attenuation of myocardial injury by DMOG was demonstrated in the rabbit ischemia reperfusion model. In NGF deprived neurons DMOG increased cell survival through inhibition of cytochrome c release." SOURCE

 santa cruz biotechnology, inc.

PLEASE DON'T TAKE DMOG WITHOUT BEING IN A CLINICAL TRIAL!  (CRBCM OPINION PROTECTED BY THE FIRST AMENDMENT!)

CANCER CURE IN PHASES /CANCER MODE
------------------------------------------------------

Now it is clear to those that are deep in the fight against cancer that cancer cell can be attacked at different cellular phases or layers:
1. The membrane Phase: where receptors, stimuli, integrins and Actinic based pathways are in actions.
*talking about  Receptors on should include notably the Death Receptors which could trigger Caspase cascade at membrane stimulation.  It goes without saying that the cell hide these Death receptors well throwing all kind of barriers, inhibitors and decoy receptors.   If you find these Death receptors, cure is yours.  Cancer cells makes these death Receptor few and far apart by clearly methylating or suppressing the genes involved in their expression.  In therapeutic Targeting, Receptors of  growth factors have been the most looked at. It is now known that growth factors have both the role of causing cancers by causing secondary amplification of pathways, but also by driving cancer growth by playing an autocrine growth and giving cancer an advantage of growth over surrounding cells.  This role is critical in cancer seeding during metastasis.  One of the Growth factor that has been insufficiently looked at is the Tumor Necrosis Factor (TNF).
TNF has been poorly looked at because It can induce Necrosis that we can't control.  Necrosis is an alternative Apoptosis that is independent of Caspase induced cell death.  It is said that when a sepsis is uncontrolled it is because there is too much TNF released and we have no effective way of controlling TNF
to date.   Anti TNF product have been introduced cautiously introduced (ENBREL use in psoriasis) but warnings about overall global immune suppression tell you of danger using this modality.  And this is mostly aplha receptor suppression.  Work is in progress in this area. 

Some tumor growth factor actually control or impact the expression of ICAMS, the adhesion molecules including the Cadherins which are decreased prior to cancer Metastasis or readiness  to be on the move!
 
*Stimuli are chemical, traumatic, pressure like but also growth driven.  In cancer biology, they involve the pathogenesis of cancers as they leading to causing it (ie. Esophageal and lung cancers), but they also involve cancer growth and cell survival.  It is the stimulus interpretated as stress that will reach the c-JUN instead of the regular MAPK pathway.  The MTOR will insure cancer or cell survival through their multiple effect which include thier impact of Telomeres!
Through c-JUN, proliferation or overproduction of Cyclins and growth factors will secondarily occur or expand to amplify the actions.   Cyclins and growth factors belongs to the Integrins mentioned above.  Every molecule belonging to the Integrins is attached a specific family of Metalloproteases.   We believe that this is doe through a Flippase and floppase modality (don't forget the scramblase modality).   In essence, when cyclin molecule is thrown in the cytoplasm, a Metalloprotease in thrown in the Extracellular space. Metalloproteases act as collagenase and open the road for cell migration.   The cell has collagen also in its membrane.  It is clear that knowing its metalloprotease, it will make an inhibitor that covers and protect its own Collagen structure.  It is believed that the insufficiency of these inhibitors lead to autodistruction of the cell in TTP.  But that is another topic.

*Actinic based pathways lead to a quick notification by the nucleus of what is going on the cell surface. Microtubules act as nerve for the cell and through the Reticulum Endothelium, take the message to the cell faster for initiation of the Nuclear Phase, by-passing the Cytoplasmic phase.  The Wnt pathway seems globally to take this approach and is important in Breast and Ovarian Cancer.  We will revist this topic at length!

2. Cytoplasmic Phase

Receptors and stimuli are the critical determinants of this phase.  And Growth factors, pyrogenes, and various stimuli act on receptors which are transmenbrane  (Decoy receptors lack a post membrane section) and therefore can trigger an intramembrane stimulation of the GTPase and other molecule complexes attached to the membrane at the inside surface,  the SRC and RAS families are located in this area  (to be continued.)

DO NOT CLAIM THAT I DID NOT TELL YOU (FYI)

DO NOT CLAIM THAT I DID NOT TELL YOU (FYI)

From: Health Alert Network (CDC) [mailto:healthalert@cdc.gov]
Sent: Friday, April 05, 2013 1:24 PM
To: Health Alert Network (CDC)
Subject: Errata for CDC HAN 344: Human Infections with Novel Influenza A (H7N9) Viruses

Dear HAN Coordinators,

Please see the two errata below that need to be incorporated into cascaded notification of CDC HAN 344. In the Treatment section the comma between oseltamivir and inhaled zanamivir was removed and replaced with the word or.  This change is important for clinical reasons.  In the For More Information section the typo in the final link to source should be corrected from Veterans to Veterinarians.

Treatment
    For persons hospitalized with suspected influenza, including suspected novel H7N9 virus infection, clinicians should start empiric treatment with influenza antiviral medications (oral oseltamivir or inhaled zanamivir) as soon as possible, without waiting for laboratory confirmation.
    For high-risk persons (persons <5 years of age, ≥65 years of age, and those with certain underlying medical conditions) with suspected influenza of any severity , including suspected novel H7N9 virus infection, clinicians should start empiric treatment with influenza antiviral medications (oral oseltamivir or inhaled zanamivir) as soon as possible, without waiting for laboratory confirmation.
For More Information
    National Association of State Public Health Veterinarians "Compendium of Measures to Prevent Disease Associated with Animals in Public Settings, 2011" is available as the first bulleted item at http://nasphv.org/documentsCompendiumAnimals.html.

Regards.
CDC HAN Team

Indiana Health Alert Network

This is an Official
Indiana Health Alert Network Advisory Message

STRATIFIN (IN OVARIAN CANCER)

LAM et al.

 " Stratifin, also known as 14-3-3 sigma protein, stimulates matrix metalloproteinase (MMP)-1 expression in dermal fibroblasts.  Treatment of dermal fibroblasts with stratifin resulted in rapid and transient upregulation of c-jun and c-fos mRNA levels.  Stratifin was demonstrated to increase MMP-1 protein levels. Microarray analysis of stratifin-treated fibroblasts shows an increase in Elk4/Sap1 mRNA expression and this finding was confirmed by northern blot analysis. Our results indicate that stratifin markedly increase Elk4/Sap1 mRNA expression in a time-dependent fashion. In conclusion, stratifin stimulates fibroblast MMP-1 levels through the activation of c-fos and MAPK pathway."

Our interpretation is that stratifin is part of an intergrin, its release in the Cytoplasm indeed stimulate MAPK C-JUN and c-fos.  This means it is interpretated by the cell as a chemical stressor. The NF-kB is not far away.  One of the most important hidden information here is the note by the authors that there is an increase of ELK4/Sap1.

ELK4 has been shown to interact with Serum response factor^[4][5] and BRCA1.^[6]

Serum response factor has been shown to interact with NFYA,^[10] Src,^[11] CREB-binding protein,^[12] GTF2I,^[13][14] ATF6,^[15] Nuclear receptor co-repressor 2,^[16] CEBPB,^[17][18] GATA4,^[19][20] Myogenin,^[21][22] GTF2F1,^[23][24] TEAD1,^[25] ELK4,^[15][26] Promyelocytic leukemia protein^[12] and ASCC3.^[27]

(wikipedia)

(PLEASE, WHEN A MOLECULE INTERACT WITH THIS MANY MOLECULE, IT IS A PERFECT, LEGITIMATE TARGET FOR THERAPY, AND SFR DOES)

ELK4 therefore control BRCA1 and serum response factor which control NFYA.  This uncover what the cancer cell has to do to start the neoplastic process.  It has to derail genetic repair by abrogating the action of BRAC1, but it also has to take controles of CBF complexes  and NFYA and ZHXY.  Remember CBF complexes control the direction of the metabolism, In essence, when it comes to function in the cell,  the role of Core Binding Factors (CBF) is indistinguishable from that of TRANSCRIPTION FACTORS.  They all impose the direction that the cell metabolism should take.

Remember also that because the Stratifin engages the MAPK mostly through the certain well selected CDK, it will tend to stop cell division.  In Breast cancer, Stratifin is one of the earliest methylated gene slated for silencing.

CDO1:
 Cysteine dioxygenase type I, IS A GENE CONTROLLING  CYSTEIN METABOLISM. DEEP ANALYSIS BRINGS THIS GENE TO ELECTRON EXCHANGE FOR THE FORMATION OF CYTOCHROME C, THE WAY TO APOPTOSIS.  THE CANCER CELL QUICKLY METHYLATES THIS GENE EARLY AND MUTATION HAS BEEN LINKED TO PROGNOSIS
 (WORK FROM CORNELL UNIVERSITY)

Nomenclature of 2 important genes in Ovarian cancer !

1.RASSF1A:  One of the thing cancer cell do is to Methylate some genes in order to block its path to death.
it appears this gene is a critical door to shut or disable.  It not only decrease the significance of RAS and MAPK in the pathogenesis of tumor that harbor this mutation.   It also remove blockage to proliferation by desensitizing the cell to the effect of P53, Cyclins.  Desensitize the cell to Death Receptor 6 and its Fas connection.  RASSF1a, demethylation is a valid target in ovarian cancer.

2.HNF1B:  " Hepatocyte Nuclear Factor 1α (HNF1α) is an atypical homeodomain-containing transcription factor that transactivates liver-specific genes including albumin, α-1-antitrypsin and α- and β-fibrinogen. Biallelic inactivating mutations of HNF1A have been frequently identified in hepatocellular adenomas (HCA), rare benign liver tumors usually developed in women under oral contraceptives, and in rare cases of hepatocellular carcinomas developed in non-cirrhotic liver. HNF1α-mutated HCA (H-HCA) are characterized by a marked steatosis and show activation of glycolysis, lipogenesis, translational machinery and mTOR pathway. We studied the consequences of HNF1α silencing in hepatic cell lines, HepG2 and Hep3B and we reproduced most of the deregulations identified in H-HCA."
 (Laura Pelletier et al)
This gene is the gene of differentiation for liver formation, it has the structure of a CBF (core binding Factor) therefore has a subunit binding the DNA, therefore silencing that portion, and another subunit having locations for enzymatic proteins or molecular structures that directly assume various functions intended by the cell (formation of Albumin, alpha Antitrypsine, and Beta Fibrinogen).
Interestingly enough, Steatosis is a prominent feature here.  This structure and gene may be of interest in LIPOSARCOMA?  
DOES ACTIVATION OF MTOR DEMONSTRATED HERE OPEN THE DOOR TO THE USE OF MTOR IN LIPOSARCOMA?

WE CONTINUE TO BE STOPPED IN OUR PROGRESS BECAUSE OF LACK OF FUNDING

IN THE UNITED STATES THE SCARCITY OF FUNDING HAS BECOME A HINDRANCE TO THE CURE PROMPTING THE AMERICAN CANCER SOCIETY TO LAUNCH A TELEVISION CAMPAIGN  ASKING PEOPLE TO TAKE THIS CAUSE BACK TO THE STREET.  THE AMERICAN CONGRESS IS SHACKLED IN DIVISIONS THAT HAVE NOW BECOME VISCERAL AND NONSENSICAL.  AMERICA HAS LOST ITS DREAMERS AND THEREFORE ITS INSPIRING IDEALS.  UNDER THE PRETENSE OF FINANCIAL PRUDENCE, DREAMS ARE ALLOWED TO DIE, CURE LET TO ESCAPE ONE MORE DAY, AND CANCER VICTIMS ARE LET TO DIE IN THE PROCESS!  (WE NEED LINCOLN BACK!)
"LET'S GET LOUD" THE CANCER AGENCY ADVOCATES, AND THE CRBCM SUPPORTS THE MOVEMENT!
ANOTHER COMPONENT TO THE PROBLEM, WITH SCARCITY COME MORE POLITICAL FAVORS, MORE DISCRIMINATION AND DISPARITY IN GRANT ALLOCATIONS.  THE CRBCM DOES NOT EXPECT ANYTHING AT PRESENT.  THE IRS IS STILL FIGHTING US BY SHACKLING OUR 501 STATUS.  SUPPRESSION OF MINORITY RESEARCH POTENTIAL COMES IN ALL UGLY FORMS!  WE WILL NOT BACK DOWN UNTIL THEIR PLAY BECOME IRRELEVANT TO THE COURSE OF HISTORY!  CPRIT HAS PLAYED FAVORITISM, LOOK WHERE THEY ARE...DO THE RIGHT THING PEOPLE, NO ONE HAS REACHED THE MOON BY FAULTY MATH BECAUSE NATURE IS WATCHING!  AT THE CRBCM, THE FIGHT IS ON, WE ARE NOT GOING ANYWHERE AND STAY IN
THE GAME UNTIL OUR VOICE IS HEARD, UNTIL OUR ENEMIES BECOME IRRELEVANT AND UNTIL WE ARE ALLOWED TO RISE!

Nomenclature of some Genes in Ovarian Cancer:

Nomenclature of some Genes in Ovarian Cancer:

BRAC1
BRAC2
CDO1
HER-2
CPG ISLAND
TMS1
ER alpha
PRB
MEK
==============================================================
RASSF1A:  One of the thing cancer cell do is to Methylate some genes in order to block its path to death.
it appears this gene is a critical door to shut or disable.  It not only decrease the significance of RAS and MAPK in the pathogenesis of tumor that harbor this mutation.   It also remove blockage to proliferation by desensitizing the cell to the effect of P53, Cyclins.  Desensititize the cell to Death Receptor 6 and its Fas connection.  RASSF1a, demethylation is a valid target in ovarian cancer
RARbeta
=============================================================

STRATIFIN.

LAM et al.

 " stratifin, also known as 14-3-3 sigma protein, stimulates matrix metalloproteinase (MMP)-1 expression in dermal fibroblasts.  Treatment of dermal fibroblasts with stratifin resulted in rapid and transient upregulation of c-jun and c-fos mRNA levels.  Stratifin was demonstrated to increase MMP-1 protein levels. Microarray analysis of stratifin-treated fibroblasts shows an increase in Elk4/Sap1 mRNA expression and this finding was confirmed by northern blot analysis. Our results indicate that stratifin markedly increase Elk4/Sap1 mRNA expression in a time-dependent fashion. In conclusion, stratifin stimulates fibroblast MMP-1 levels through the activation of c-fos and MAPK pathway."

Our interpretation is that stratifin is part of an intergrin, its release in the Cytoplasm indeed stimulate MAPK C-JUN and c-fos.  This means it is interpretated by the cell as a chemical stressor. The NF-kB is not far away.  One of the most important hidden information here is the note by the authors that there is an increase of ELK4/Sap1.

ELK4 has been shown to interact with Serum response factor^[4][5] and BRCA1.^[6]

Serum response factor has been shown to interact with NFYA,^[10] Src,^[11] CREB-binding protein,^[12] GTF2I,^[13][14] ATF6,^[15] Nuclear receptor co-repressor 2,^[16] CEBPB,^[17][18] GATA4,^[19][20] Myogenin,^[21][22] GTF2F1,^[23][24] TEAD1,^[25] ELK4,^[15][26] Promyelocytic leukemia protein^[12] and ASCC3.^[27]

(wikipedia)

ELK4 therefore control BRCA1 and serum response factor which control NFYA.  This uncover what the cancer cell has to do to start the neoplastic process.  It has to derail genetic repair by abrogating the action of BRAC1, but it also has to take controles of CBF complexes  and NFYA and ZHXY.  Remember CBF complexes control the direction of the metabolism, In essence, when it comes to function in the cell,  the role of Core Binding Factors (CBF) is indistinguishable from that of TRANSCRIPTION FACTORS.  They all impose the direction that the cell metabolism should take.

Remember also that because the Stratifin engages the MAPK mostly through the certain well selected CDK, it will tend to stop cell division.  In Breast cancer, Stratifin is one of the earliest methylated gene slated for silencing.

======================================================================
HNF1B " Hepatocyte Nuclear Factor 1α (HNF1α) is an atypical homeodomain-containing transcription factor that transactivates liver-specific genes including albumin, α-1-antitrypsin and α- and β-fibrinogen. Biallelic inactivating mutations of HNF1A have been frequently identified in hepatocellular adenomas (HCA), rare benign liver tumors usually developed in women under oral contraceptives, and in rare cases of hepatocellular carcinomas developed in non-cirrhotic liver. HNF1α-mutated HCA (H-HCA) are characterized by a marked steatosis and show activation of glycolysis, lipogenesis, translational machinery and mTOR pathway. We studied the consequences of HNF1α silencing in hepatic cell lines, HepG2 and Hep3B and we reproduced most of the deregulations identified in H-HCA."
 (Laura Pelletier et al)
 This gene is the a gene of differentiation for liver formation, it has the structure of a CBF (core binding Factor) therefore has a subunit binding the DNA therefore silencing that portion, and another subunit having locations for enzymatic proteins or molecular structures that direct assume various functions intended by the cell (formation of Albumin,alpha Antitrypsine, and Beta Fibrinogen)  Interestingly enough, Steatosi is a prominent feature here.  This structure and gene may be of interest in LIPOSARCOMA.?   DOES ACTIVATION OF MTOR DEMONSTRATED HERE OPEN THE DOOR TO USE OF MTOR IN LIPOSARCOMA?
-------------------------------------------------------------------------------------------------------------
p16INK4A
p14
CYCLIN D2
SLIT2
CDH13
PTEN
CLAUDIN 3,4
HE4
MUCIN1 OR MUC1
MESOTHELIN
ApoE, J
PIK3CA
P53 AND CHEK2
MLH1
MSH2,6
PMS2
CA-125
STK11
LKB1
PTCH
ATM

This is just the beginning, lets go to work! love those recurring genes as they cross over with presence in other cancers to strengthen their importance, Please remember those that lead to hypothrophy of muscles and extremities are probably more important for therapeutic intervention.  And those with a "q" location on chromosome arm are most likely of poor prognosis or dramatic phenotype expression!  Always do remember that Multidrug resistance (MDR-1) is in play  HERE!

GENES IN OVARIAN CANCER: (part I)

The notion that there is a particular gene or genes for a specific cancer is attractive, but most of the time only reflects the scientists' tendency to attract the community interest on their findings.  There is nothing wrong with that because their work needs recognition. Recent advances in cure and novel therapeutic approaches have occurred to convince the common of mortals that Researchers are hard at work.  But by now we know that most standard genetic family abnormalities involve only 5-10% of cancers.  That means that no one genetic abnormality stands to justify any specific cancer in-toto. The case of BRCA1 and 2 in Breast cancer.
Breast cancer survivor Women who participated in My talk in El Paso,TX were surprised to learn that 85% of women newly diagnosed with Breast cancer in the US were first in their family.  Everybody was assuming that breast cancer happens because of family predisposition.  This is clearly an underestimation of the heterogeneity of our genetic material.  Don't understand me wrong, there are clear cases of family predispositions, however, we have an approximate 25,000 genes, something and somewhere a significant event can happen anytime.  Also, one should know that there is primary and secondary amplification.  In some cases it is hard to determine which came first (Chicken and egg dilemma ).
Another compounding factor complicating our interpretation in rare cases, is the notion that the cause of cancer can be located in the promoter gene which all of a sudden becomes difficult to methylate or suppress, causing secondary amplification of a gene or of its regulators.
When one wants to look at the genes involved in ovarian cancers, it is good to focus on particular genes (HNF1B) as clearly publicized, but we can't ignore the story of BRCAs, and other family syndromes which harbor Ovarian cancer as a component of the syndrome.  Therapies that are being developed and being effective in Ovarian cancer (Anti MEK) are also pointing to relevant genes.   The story of lung cancer with its ever expanding list of DRIVER MUTATIONS and the advent of MULTIPLEX gene screening is just another proof of the danger of claiming to have discovered THE GENE for a specific cancer!

GENES OF OVARIAN CANCER (to follow)

Secondary Hematologic Malignancies

Japanese researchers suggested in a retrospective study of patients treated with Temodar for Glioma, that there is an increased occurrence of secondary Myelodysplasia, leukemias and particularly Acute Lymphoblastic Leukemia.  It is interesting to look further, beyond the simple observation and speculate as to what leads to such a transformation at the gene level.
Leukemias are a disease not only of pathways, but of deep derangement at the Histone-DNA level and include particularly not only protein complexes similar to core binding factors, but also regulator genes which appear to be specifically amplified in leukemias!
It is pertinent to also look closer at Proteins Kinases affecting or interacting with DNA.  Temodar is an Alkylating agent per the researcher's report.
The interval between the treatment and the occurrence is also interesting, and suggests that the secondary Leukemia results from a secondary amplification of proliferative genes after the onslaught on cellular receptors by the chemical stimulus. The NK-kB, c-JUN must be in play.  Blocking these pathways could prevent such malignant occurrence. We will soon find that secondary malignancy could be prevented by simply blocking some tumor growth factors.  We don't need to accept these complications any more.  I learned that my first patient who was diagnosed with Hodgkin disease, a curable disease, died later on with an Acute Leukemia.  She was free of Hodgkin disease. Our current follow-up is inadequate in this regard, as we sit and wait for secondary leukemia to set in.  Lets look into blocking Tumor growth factors to stop secondary leukemias!

CRITICAL GENES IN (SECONDARY) LEUKEMIA

Aside from the the genes that can block Tumor Growth factors, our discussion on leukemia had shown that Leukemia is driven also by proteins located at CBF.  Indeed we now know that the proteins found in the CBF indeed determine the direction and intensity of the the neoplastic process.  Attacking growth factors effectiveness at stimulating its relevant receptor appears to be a decent strategy.   However there are other gene that should be in the focus of our attention.
AP-1
TFE-3
SMAD2-4
FOXG1
and at the border JARID1B
(we will add some gene regulators to this list)
==========================================================
'"The SMAD4 gene provides instructions for making a protein involved in transmitting chemical signals from the cell surface to the nucleus. This signaling pathway, called the transforming growth factor beta (TGF-β) pathway, allows the environment outside the cell to affect how the cell produces other proteins. The signaling process begins when a TGF-β protein attaches (binds) to a receptor on the cell surface, which activates a group of related SMAD proteins. The SMAD proteins bind to the SMAD4 protein and form a protein complex, which then moves to the cell nucleus. In the nucleus, the SMAD protein complex binds to specific areas of DNA where it controls the activity of particular genes and regulates cell growth and division (proliferation).

By controlling gene activity and regulating cell proliferation, the SMAD4 protein serves both as a transcription factor and as a tumor suppressor. Transcription factors help control the activity of particular genes, and tumor suppressors keep cells from growing and dividing too fast or in an uncontrolled way.

Does the SMAD4 gene share characteristics with other genes?

"The SMAD4 gene belongs to a family of genes called SMAD (SMAD, mothers against DPP homologs).
A gene family is a group of genes that share important characteristics. Classifying individual genes into families helps researchers describe how genes are related to each other. For more information, see What are gene families? in the Handbook."  

 "Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for syngernistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator."
(NIH)

MSR1, ASCC1, and CTHRC1 (Nomenclature of Genes in Esophageal cancer)

CTHRC1" is a  protein that has the ability to inhibit collagen matrix synthesis.
  Expression of Cthrc1 is increased in fibroblasts and chondrocytic cells in response to TGF-beta family members including BMP4, BMP2 and TGF-beta. Cthrc1 is also upregulated during tumorigenesis and metastasis;
CTHRC1 has been linked to major signaling pathways such as Wnt and TGF-beta. The ability of CTHRC1 to inhibit TGF-beta signaling via a reduction in Smad 2/Smad 3  (is to be noted!)
Location 8q22.3. (Leclair at al )

Once again this comment suggests that stimulation of growth factor induced secondarily by NF-kB /c-JUn amplification leads to secondary amplification which in this case happens to  this gene.  This gene comes into play in vascular remodeling suggesting invasiveness of the cancer.  This is the stuff used by neurone to find their way down their passage. If it is expressed it marks cellular invasiveness.  Please pay marked attention to the pathway with witch it is identified, a pathway we believe is very important but neglected. The Wnt pathway.  This is the metastasis pathways, it correlates with metastatic disease and is the stuff you find in triple negative Breast cancer!   
Suppression of Smad2 could prevent cancer induced by Irritations?  and may be secondary cancers?

2.ASCC1.
This gene encodes a subunit of the activating signal cointegrator 1 (ASC-1) complex. The ASC-1 complex is a transcriptional coactivator that plays an important role in gene transactivation by multiple transcription factors including activating protein 1 (AP-1), nuclear factor kappa-B (NF-kB) and serum response factor (SRF). The encoded protein contains an N-terminal KH-type RNA-binding motif which is required for AP-1 transactivation by the ASC-1 complex. Mutations in this gene are associated with Barrett esophagus and esophageal adenocarcinoma. Alternatively spliced transcripts encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Dec 2011]""  (danielsen et al!)

Activating signal cointegrator 1 complex subunit 1 (ASCC1) is a subunit of the activating signal cointegrator 1 (ASC-1) complex. The ASC-1 complex is a transcriptional coactivator that plays an important role in gene transactivation by multiple transcription factors including activating protein 1 (AP-1), nuclear factor kappa-B (NF-kB) and serum response factor (SRF). ASCC1 contains an N-terminal KH-type RNA-binding motif which is required for AP-1 transactivation by the ASC-1 complex. Mutations in the ASCC1 gene are associated with Barrett esophagus and esophageal adenocarcinoma [taken from NCBI Entrez Gene (Gene ID: 51008)].

Alternative names for ASCC1 Antibody include activating signal cointegrator 1 complex subunit 1 antibody, ASC-1 complex subunit p50 antibody, Trip4 complex subunit p50 antibody, p50 antibody, CGI-18 antibody, ASC1p50 antibody.

I refuse to comment on this one because it is so obvious, this is at the core of pathogenesis where chronic stimuli act through the NF-kB and C-JUN to induce growth factors which eventually stimulate a secondary amplification that leads to the pathogenesis of cancer, additional mutations such as that occurring in CTHRC1 will complete the dance.  This ASCC1 appears to be a CBF like molecular complex driving this transformation and therefore it is a valid target for therapy.

MSR1
already discussed

Update on CPRIT Grant Moratorium

Update on CPRIT Grant Moratorium
In a March 19 letter to the Oversight Committee, the Governor, Lieutenant Governor, and Speaker of the House authorized CPRIT to move forward with the 25 researcher recruitment grants approved by the Oversight Committee in August and December 2012.
Once information becomes available regarding the remaining August and December awards that are awaiting final contracts, an update will be posted on CPRIT’s website.

The following is a statement released March 20 from Wayne Roberts, Interim Executive Director of CPRIT:

The Cancer Prevention and Research Institute of Texas has been informed that state leadership has authorized the agency to move forward with the 25 researcher recruitment grants approved by the CPRIT Oversight Committee in August and December. These grants have been awaiting final contracts, pursuant to the moratorium instituted by the Governor, Lt. Governor and Speaker on December 18. Each of these grants has been certified as being reviewed and approved using appropriate processes and procedures.

We are grateful to the Governor, Lt. Governor, and Speaker for allowing CPRIT to proceed with these important recruitment awards. We will continue to work with them and all members of the Legislature to make sure they have the information they need to determine how they want CPRIT to operate going forward.  We have worked hard to regain trust with our elected officials and the citizens of Texas. We take this action as evidence that some progress has been made and we will continue to work to strengthen this trust during the coming weeks and months.

AG investigating CPRIT Foundation

AG investigating CPRIT Foundation

Nomenclature of genes in Esophageal cancer (continued)

FEZ1 ,  fasciculation and Elongation protein Zeta,
a significant gene intervening in the motility of the Esophagus.
Alteration of this gene also increases cancer susceptibility to viral infection (HIV).
It interacts with NBR1, a gene that confers a certain refractoriness to this cancer
and supports the Idea that Cisplatin may be essential to treatment in this disease.
In fact, several neurological receptors are involved in Esophageal cancer
and may contribute to the disease's poor prognosis and epithelial morphology presentation.

RHBF2
--------